Ovarian Cancer Trial Result: Positive immune response and 
improved response to previously failed traditional therapies

Exposure to a medically induced high fever, under the HEATT® procedure, stimulates innate immune pathways as indicated by cytokine signaling. This upregulation of the immune response contributes to the body’s defenses which attacks remaining cancer cells. Data collected from autopsy showed tumor infiltration by lymphocytes in the ovarian trial and implies this process as a benefit of HEATT®.


Seven patients received chemotherapy regimens after completing HEATT®. All seven responded to chemotherapy regimens that they had failed previously, before HEATT®, including localized hyperthermia, radiation therapies, and chemotherapies. The increase in survival suggests at least a reset of molecular mechanisms known as thermal sensitization.